The impact of restless legs syndrome: a familial case study.
Restless legs syndrome (RLS) is a common neurological disorder characterized by an irresistible urge to move. RLS has a general population incidence of between 5% and 10% and a familial rate as high as 77%. This case study examines the pathophysiology, diagnosis, and treatment along with the presentation of RLS in two members of a family with near-identical onset and treatment. Cases of familial RLS may be best directed toward similar treatment regimens.
Scott
S
Snider
D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D052160:Benzothiazoles / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004338:Drug Combinations; D005192:Family Health; D006801:Humans; D015994:Incidence; D007211:Indoles / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077487:Pramipexole; D015995:Prevalence; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology
D000701:Analgesics, Opioid; D000927:Anticonvulsants; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004338:Drug Combinations; D007211:Indoles; C009265:carbidopa, levodopa drug combination; C046649:ropinirole; D001569:Benzodiazepines; D007980:Levodopa; D000077487:Pramipexole; D002230:Carbidopa